PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AstraZeneca, Daiichi Sankyo grab first FDA approval for targeted HER2-low breast cancer drug

The U.S. FDA has approved the first targeted therapy for patients with HER2-low breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu.

Enhertu is now available as a third third-line treatment for women with advanced HER2-positive breast cancer. HER2-low breast cancer is a newly defined subset of HER2-negative breast cancer, which means the tumours do not over-express the HER2 protein.

Out of the nearly 300,000 breast cancer cases diagnosed each year, between 80-85% of them can be categorized as HER2-negative subtype (including hormone receptor-positive and triple-negative breast cancer).

The approval was granted under the FDA’s Real-Time Oncology Review program after Enhertu secured Priority Review and Breakthrough Therapy designations. The FDA nod hinged on results from the DESTINY-Breast04 trial, a randomized study that included 557 adult patients in unresectable — or difficult to remove — or metastatic cancer. Results showed significant improvement in progression-free survival and overall survival.

Richard Pazdur, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research reiterated the importance of the approval, stating that “Having therapies that are specially tailored to each patient’s cancer subtype is a priority to ensure access to safe and innovative treatments.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026